Author:
Yi Shuhua,Cai Zhen,Hu Yu,He Aili,Gao Sujun,Li Qian,Sha Linlin,Zhang Nating,Ren Yupeng,Gai Xue,Yang Xue,Qin Rui,Qiu Lugui
Funder
Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Janssen Research & Development, LLC
Janssen Global Services
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference18 articles.
1. Dogliotti I, Jimenez C, Varettoni M, et al. Diagnostics in Waldenstrom’s macroglobulinemia: a consensus statement of the European Consortium for Waldenstrom’s Macroglobulinemia. Leukemia. 2022;37(2):388–95.
2. Steingrímsson V, Landgren O, Kristinsson SY. Epidemiology of Waldenström macroglobulinemia. In: Leblond V, Treon S, Dimoploulos M, editors. Waldenström’s macroglobulinemia. Cham: Springer; 2017. p. 97–109.
3. Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(S4):iv41–50.
4. Hematology Oncology Committee of China Anti-Cancer Association, Chinese Society of Hematology Chinese Medical Association, Chinese Working Group of Walderstrom Macroglobulinemia. [Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma/Walderstrom macroglobulinemia (2022)]. Zhonghua Xue Ye Xue Za Zhi. 2022;43(8):624–30.
5. Ravi G, Kapoor P. Current approach to Waldenström macroglobulinemia. Cancer Treat Res Commun. 2022;31:100527.